Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 3 3Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Precancerous Conditions 1Neoplasms 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Fenretinide × Clear all
NCT00004154 2018-11-08

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

M.D. Anderson Cancer Center

Phase 3 Completed
111 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT01479192 2018-11-07

Fenretinide in Healthy Young Women at Genetic and Familial Risk

European Institute of Oncology

Phase 3 Terminated
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00003075 2018-10-24

Fenretinide in Treating Patients With Cervical Neoplasia

M.D. Anderson Cancer Center

Phase 3 Completed
39 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡